Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other financing activities (2020 - 2023)

4D Molecular Therapeutics (FDMT) has disclosed Other financing activities for 4 consecutive years, with $260000.0 as the latest value for Q2 2023.

  • On a quarterly basis, Other financing activities rose 205.69% to $260000.0 in Q2 2023 year-over-year; TTM through Jun 2024 was $329000.0, a 58.72% decrease, with the full-year FY2022 number at $468000.0, changed N/A from a year prior.
  • Other financing activities was $260000.0 for Q2 2023 at 4D Molecular Therapeutics, up from $69000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $946000.0 in Q1 2021 to a low of -$946000.0 in Q4 2021.
  • A 4-year average of $81700.0 and a median of $157500.0 in 2022 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: tumbled 74.0% in 2022, then soared 205.69% in 2023.
  • 4D Molecular Therapeutics' Other financing activities stood at -$348000.0 in 2020, then crashed by 171.84% to -$946000.0 in 2021, then soared by 149.47% to $468000.0 in 2022, then tumbled by 44.44% to $260000.0 in 2023.
  • Per Business Quant, the three most recent readings for FDMT's Other financing activities are $260000.0 (Q2 2023), $69000.0 (Q1 2023), and $468000.0 (Q4 2022).